Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode™ Whole Transcriptome ...
BostonGene, developer of the leading AI foundation model for tumor and immune biology, announced results from the FEASY study ...
Enabled by its exclusive license of CoolMPS technology, Swiss Rockets AG is developing its first sequencer, CoolMPS 600, through contract R&D with Complete Genomics since August 2025. The platform is ...
New Trailmaker functionality integrates immune repertoire and whole transcriptome data to deliver rapid, publication-ready insights Parse Biosciences, the leading provider of accessible and scalable ...
We validated a clinical bait-capture WTS assay using 78 solid tumor samples across diverse tissue types, including 59 with known fusions or oncogenic splice variants. Sensitivity was assessed against ...
Combines BioSkyrb’s new ResolveOME™ Whole Genome and Transcriptome Single-Cell Core Kit 384-well assay with Uno Single Cell Dispenser™ provided by Tecan in a single workflow Enables scalable, ...
Clinical significance of c-Met expression in patients with advanced gastroesophageal adenocarcinoma. This is an ASCO Meeting Abstract from the 2026 ASCO Gastrointestinal Cancers Symposium. This ...
What makes a chili pepper spicy, colorful, and full of flavor? Scientists have now decoded the genetic journey behind pepper development, using long-read sequencing to build the most comprehensive ...
Immunotherapy has been a revolutionary breakthrough for cancer therapeutics, but it is still hampered in that it only benefits certain patients. Moreover, the molecular determinants of immunotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results